• 1
    Grossman CJ. Interactions between the gonadal steroids and the immune system. Science 1985;227:257 61.
  • 2
    Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981;53:174 8.
  • 3
    Lahita RG, Kunkel HG, Bradlow HL. Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum 1983;26:1517 21.
  • 4
    Steinberg AD, Huston DP, Taurog JD, Cowdery JS, Raveche ES. The cellular and genetic basis of murine lupus. Immunol Rev 1981;55:121 54.
  • 5
    Theofilopoulos AN, Kofler R, Singer PA, Dixon FJ. Molecular genetics of murine lupus models. Adv Immunol 1989;46:61 109.
  • 6
    Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A. Induction of transforming growth factor beta 1 in human breast cancer in vivo following Tamoxifen treatment . Cancer Res 1992;52:4261 4.
  • 7
    Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of Tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507 17.
  • 8
    O'brian CA, Liskamp RM, Soloman DH, Weistein IB. Inhibition of protein kinase C by Tamoxifen. Cancer Res 1985;45:2462 5.
  • 9
    Chakravarty N. The roles of carmodulin and protein kinase C in histamine secretion from mast cells. Agents Actions 1992;36:183 91.
  • 10
    Wiseman H. Tamoxifen: new memrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 1994;15: 83 9.
  • 11
    Cheng AL, Chuang SE, Fine RL et al Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998;55:523 31.
  • 12
    Lφnning PE, Hall K, Aakvaag A, Lien EA. Influence of Tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992;52:4719 23.
  • 13
    Huynh HT, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by Tamoxifen. Cancer Res 1993;53:1727 30.
  • 14
    Baral E, Nagy E, Berczi I. Modulation of natural killer cell-mediated cytotoxicity by Tamoxifen and estradiol. Cancer 1995;75:591 9.
  • 15
    Drach J, Gsur A, Hamilton G et al Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-γ in normal human T lymphocytes. Blood 1996;88: 1747 54.
  • 16
    Wu WM, Suen JL, Lin BF, Chiang BL. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology 2000;100:110 8.
  • 17
    McNeilly F, Kennedy S, Moffett D et al A comparison of in situ hybridition and immunohistochemistry for the detection of a porine circovirus in formalin-fixed tissues from pigs with post-weaning multisystemic wasting syndrome (PMWS) . J Virol Methods 1999;80:123 8.
  • 18
    Aderka D, Wysenbeek A, Engelmann H et al Correlation between serum levels of souble tumor necrosis factor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111 20.
  • 19
    Gabay C, Cajir N, Moral F et al Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303 8.
  • 20
    Herzenberg LA, Stall AM, Lalor PA, Moore WA, Parks DR. The Ly-1 B cell lineage. Immunol Rev 1986;93:81 102.
  • 21
    Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 and CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063 73.
  • 22
    Koshy M, Berge D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98:826 37.
  • 23
    Kincade PW, Lee G, Fernandes G. Abormalities in clonable B lymphocytes and myeloid progenitors in autoimmune NZB mice. Proc Natl Acad Sci USA 1979;76:3464 8.
  • 24
    Kastner DL & Steinberg AD. Determinant of B cells hyperactivity in murine lupus. Concepts Immunopathol 1988;6:22 88.
  • 25
    Takeno M, Hirayama K, Sakane T. The pathogenic role of Th2 cells in systemic lupus erythematosus (Abstract). Arthritis Rheumatism (Suppl ) 1992;35:S159.
  • 26
    Umland SP, Go NF, Cupp JE, Howard M. Responses of B cells from autoimmune mice to IL-5. J Immunol 1988;142:1528 35.
  • 27
    Cawley D, Chiang BL, Naiki M, Ansari A, Gershwin ME. Comparison of the requirements for cognate T cells help for IgG anti-dsDNA antibody production in vitro: lines for B cells from NZB.H-2bm12 but not B6. H-2bm12. Mice J Immunol 1993;50:2467 77.
  • 28
    Ye YL, Suen JL, Chen YY, Chiang BL. Phenotypic and functional analysis of activated B cells of autoimmune NZB×NZW F1 mice. Scand J Immunol 1998;47:122 6.
  • 29
    Ahmed SA, Dauphinee MJ, Montoya AI, Talal N. Estrogen induced normal murine CD5+ B cells to produce autoantibodies. J Immunol 1989;142:2647 53.
  • 30
    Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-strand DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999;42:328 37.
  • 31
    Sthoeger ZM, Bentwich Z, Zinger H, Mozes E. The beneficial effect of the estrogen antagonist Tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol 1994;21:2231 8.
  • 32
    Dayan M, Zionger H, Kalush F et al The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 1997;90:101 8.
  • 33
    Lin LC, Chen YC, Chou CC, Hsieh KH, Chiang BL. Dysregulation of T helper cell cytokines in autoimmune prone NZB × NZW F1 mice. Scand J Immunol 1995;42:466 72.
  • 34
    Cope AP, Aderka D, Doherty M et al Increased levels of soluble tumor necrosis factors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160 9.
  • 35
    Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4+-T cells that induces contact-dependent B cell differentiation (help) . J Exp Med 1992;175:1091 101.
  • 36
    Yellin MJ, D'agati V, Parkinson G et al Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997;40:124 34.
  • 37
    Mohan C, Shi Y, Laman JD, Catta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470 80.
  • 38
    Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998;160:2158 65.
  • 39
    MacDonald KPA, Nishioka Y, Lipsky PE, Thomas R. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 1997;100:2404 14.
  • 40
    Gerritse K, Laman JD, Noelle RJ et al CD40–CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93:2499 504.
  • 41
    Kuroiwa T, Lee EG, Danning CL, Illei GG, McInnes IB, Boumpas DT. CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. J Immunol 1999;163:2168 75.